Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21


19304 items
3:05 PM, Jun 01, 2018  |  BioCentury | Finance

Bacterial brain

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B. The round closed on May 31 with...
2:29 PM, Jun 01, 2018  |  BioCentury | Finance

CalPERS goes direct

The strong performance of direct life science investments made by some sovereign wealth or pension funds could be part of the rationale for CalPERS’s plan to launch its own direct investment fund that could funnel...
1:08 PM, Jun 01, 2018  |  BioCentury | Finance

Distribution to innovation

Chinese drug distributor Sinopharm plans to close additional renminbi and U.S. dollar funds this year to back innovative biotechs. According to Sinopharm Capital’s Liang Deng, China National Pharmaceutical Group Corp. (Sinopharm) is the largest pharmaceutical distributor...
2:10 PM, May 25, 2018  |  BioCentury | Finance

Buyback Band-Aid

A $3 billion expansion of its share buyback program won’t help Celgene Corp. (NASDAQ:CELG) address the long-term pipeline problems that concern a trio of buysiders, who would rather see the big biotech put the spending...
12:54 PM, May 25, 2018  |  BioCentury | Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired...
11:05 AM, May 25, 2018  |  BioCentury | Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
10:40 AM, May 25, 2018  |  BioCentury | Finance

Grail’s Asia incentives

In light of Grail Inc.’s $300 million series C round from Chinese investors, the cancer detection company has several reasons to pursue a Hong Kong listing that go beyond high valuations. The series C round,...
6:09 AM, May 25, 2018  |  BioCentury | Regulation

Model alliance

An FDA pilot program on model-informed drug development could generate the information FDA needs to fulfill a commitment under PDUFA VI and answer a big industry ask: more clarity on the agency’s standards for accepting...
6:01 AM, May 25, 2018  |  BioCentury | Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The foundation...
5:04 AM, May 24, 2018  |  BioCentury | Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....